Barrier mechanisms in the brain, I. Adult brain

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 1, 1999, Pages 11-19

  Saunders, Norman R ^a   Habgood, M D ^a   Dziegielewska, K M ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Blood brain barrier; Brain vessel permeability; Cerebral endothelium; Cerebrospinal fluid; Choroid plexus; Drug delivery; Drug permeability; P glycoprotein; Sink effect; Tight junctions

Indexed keywords

BRADYKININ; CENTRAL NERVOUS SYSTEM AGENTS; GLUCOSE TRANSPORTER; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

AMINO ACID SEQUENCE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN CELL; BRAIN FUNCTION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ELECTROLYTE DISTURBANCE; ENDOTHELIUM CELL; GLUCOSE TRANSPORT SYSTEM; PREDICTION; SHORT SURVEY; TIGHT JUNCTION;

ADULT; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; DRUG DESIGN; HUMANS;

EID: 0032890649     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.02986.x     Document Type: Short Survey

References (80)

1. 1. Ehrlich P. Das Sauerstoff-Bedürfnis des Organismus. Eine Farbenanalytische Studie. Hirshwald, Berlin. 1885.
2. 2. Roux E, Borrel A. Tétanos cérébral et immunité contre le tétanos. Ann. Inst. Pasteur 1898; 12: 225-39.
3. 3. Goldmann EE. Vitalfarbung am Zentralnervensystem. Abhdl Preus. Akad. Wissensch. Physikol. Mathemat. Klasse 1913; 1: 1-60.
4. 4. Lewandowsky M. Zur lehre von der cerebrospinal flüssigkeit. Z. Klin. Med. 1900; 40: 480-94.
5. 5. Tschirgi RD. Protein complexes and the impermeability of the blood - brain barrier to dyes. Am. J. Physiol. 1950; 163: 756P.
6. 6. Davson H, Segal MB. Physiology of the CSF and Blood - Brain Barriers. CRC Press, Boca Raton. 1996.
7. 7. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System, 2nd edn. Saunders, Philadelphia. 1992.
8. 8. Saunders HR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, II. Immature brain. Clin. Exp. Pharmacol. Physiol. 1998; 26 (in press).
9. 9. Brodie BB, Kurz H, Schanker LS. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J. Pharmacol. 1960; 130: 20-5.
10. 10. Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res. 1979; 172: 354-9.
11. 11. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980; 23: 682-4.
12. 12. Pardridge WM. Brain drug delivery and blood - brain barrier transport. Drug Delivery 1993; 1: 83-101.
13. 13. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin. Wochenschr. 1974; 52: 1158-64.
14. 14. Abraham MH, Chadha HS, Mitchell RC. The factors that influence the distribution of solutes between blood and brain. J. Pharmacol. Sci. 1994; 83: 1257-68.
15. 15. Habgood MD, ZuDong L, Dehkordi LD et al. Chemical structure of drugs and blood - brain barrier permeability. J. Physiol. 1997; 505: 49P.
16. 16. Reese TS, Karnovsky MJ. Fine structural localization of a blood - brain barrier to exogenous peroxidase. J. Cell Biol. 1967; 34: 207-17.
17. 17. Nabeshima S, Reese TS, Landis DMD, Brightman MW. Junctions in the meninges and marginal glia. J. Comp. Neurol. 1975; 164: 127-70.
18. 18. Van Deurs B. Cell junctions in the endothelium and connective tissue of the rat choroid plexus. Anat. Rec. 1979; 195: 73-94.
19. 19. Broadwell RD, Balin BJ, Selcman M. Transcytotic pathway for blood-borne protein through the blood - brain barrier. Proc. Natl Acad. Sci. USA 1988; 85: 632-6.
20. 20. Broadwell RD. Transcytosis of macromolecules through the blood - brain barrier: A cell biological perspective and critical appraisal. Acta Neuropathol. 1989; 79: 117-28.
21. 21. Broadwell RD, Bakercairns BJ, Friden PM, Oliver C, Villegas JC. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. 3. Receptor-mediated transcytosis through the blood - brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 1996; 142: 47-65.
22. 22. Seitz RJ, Heininger K, Schwenddemann G, Toyka KV, Wechsler W. The mouse blood - brain barrier and blood - nerve barrier for IgG. A tracer study by the use of the avidin - biotin system. Acta Neuropathol. 1985; 68: 15-21.
23. 23. Azzi G, Bernaudin J-F, Bouchaud C, Bellon B, Fleury-Feith J. Permeability of the normal rat brain, spinal cord and dorsal root ganglia microcirculation to immunoglobulin G. Biol. Cell. 1990; 68: 31-6.
24. 24. Aihara N, Tanno H, Hall JJ, Pitts LH, Noble LJ. Immunocytochemical localisation of immunoglobulins in the rat brain: Relationship to the blood - brain barrier. J. Comp. Neurol. 1994; 342: 481-96.
25. 25. Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G. Rat choroid plexus specializes in the synthesis and secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent of that in liver. J. Biol. Chem. 1986; 261: 3475-8.
26. 26. Lolli F, Halawa I, Link H. Intrathecal synthesis of IgG, IgA, IgM and IgD in untreated multiple-sclerosis and controls. Acta Neurol. Scand. 1989; 80: 238-47.
27. 27. Sindic CJM, Monteyne P, Laterre EC. The intrathecal synthesis of virus-specific oligoclonal IGG in multiple-sclerosis. J. Neuroimmunol. 1994; 54: 75-80.
28. 28. Maynard EA, Schultz RL, Pease DC. Electron microscopy of the vascular bed of the rat cerebral cortex. Am. J. Anat. 1957; 100: 409-33.
29. 29. Oldendorf WH, Davson H. Brain extracellular space and the sink action of cerebrospinal fluid. Arch. Neurol. Psychiatr. 1967; 17: 196-205.
30. 30. Sanchez del Pino MM, Peterson DR, Hawkins RA. Neutral amino acid transport characterization of isolated luminal and abluminal membranes of the blood - brain barrier. J. Biol. Chem. 1995; 270: 14913-18.
31. 31. Pardridge WM. Vector-mediated peptide drug delivery to the brain. Adv. Drug Delivery Rev. 1995; 15: 109-46.
32. 32. Davson H. Physiology of the Cerebrospinal Fluid. Churchill, London. 1967.
33. 33. Madsen JK, Møllgård K. The tight epithelium of the Mongolian gerbil subcommissural organ as revealed by freeze-fracturing. J. Neurocytol. 1979; 8: 481-91.
34. 34. Johanson CE, Palm DE, Primiano MJ et al. Choroid plexus recovery after transient forebrain ischemia: Role of growth factors and repair mechanisms. Cell. Mol. Neurobiol. 1999 (in press).
35. 35. Pollay M, Davson H. The passage of certain substances out of the cerebrospinal fluid. Brain 1963; 86: 137-50.
36. 36. Lautier D, Canitrot Y, Deeley RG, Cole SPC. Multidrug-resistance mediated by the multidrug-resistance protein (MRP) gene. Biochem. Pharmacol. 1996; 52: 967-77.
37. 37. Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood - brain barrier sites. Proc. Natl Acad. Sci. USA 1989; 86: 695-8.
38. 38. Tatsuta T, Naito M, Oh-Hara T, Sugawara I, Tsuro T. Functional involvement of P-glycoprotein in blood - brain barrier. J. Biol. Chem. 1992; 267: 20383-91.
39. 39. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976; 455: 152-62.
40. 40. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 1993; 62: 385-427.
41. 41. Regina A, Koman A, Center MS, Couraud PO, Roux F. Multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Physiol. 1997; 505: 59P.
42. 42. Engler CB, Sander B, Larsen M, Koefoed P, Parving HH, Lundandersen H. Probenecid inhibition of the outward transport of fluorescein across the human blood retina barrier. Acta Ophthalmol. 1994; 72: 663-7.
43. 43. Gottesman MM, Currier S, Bruggemann E, Lelong I, Stein W, Pastan I. The multidrug transporter: Mechanistic considerations. Curr. Top. Membr. 1994; 41: 3-17.
44. 44. Raviv Y, Pollard HB, Brugemann EP, Pastan I, Gottesman MM. Photosensitized labelling of a functional multidrug transporter in living drug-resistant tumor-cells. J. Biol. Chem. 1990; 265: 3975-80.
45. 45. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase. Trends Biochem. Sci. 1992; 17: 18-21.
46. 46. Pennock GD, Dalton WS, Roeske WR et al. Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration. J. Natl Cancer Inst. 1991; 83: 105-10.
47. 47. Hayafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993; 53: 4595-602.
48. 48. Habgood MD. Determinants of drug penetration into the brain. Cell. Mol. Neurobiol. 1999 (in press).
49. 49. Pardridge WM. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 1997; 17: 713-31.
50. 50. Brem H. Controlled delivery to the brain. In: Gregoriadis G (ed.). Targeting of Drugs. Plenum, New York. 1990; 155-74.
51. 51. Harbaugh RE, Saunders RL, Reeder R. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 1988; 23: 693-700.
52. 52. Vrethem M, Henriksson A, Malm C, Olsson T, Ernerudh J. IG-secreting cells pass the blood - brain-barrier: Studies on kappa-light and lambda-light chain secreting cells in plasma-cell dyscrasia. J. Neuroimmunol. 1992; 41: 189-94.
53. 53. Neuwelt EA, Hill SA. Chemotherapy administered in conjunction with osmotic blood - brain barrier modification in patients with brain metastases. J. Neurooncol. 1983; 4: 195-207.
54. 54. Mykleburst A, Helseth A, Breistol K, Hall WA, Fodstad Ÿ. Nude rat models for human tumor metastasis to CNS. Procedures for intracarotid delivery of cancer cells and drugs. J. Neurooncol. 1994; 21: 215-24.
55. 55. Brightman MW, Hori M, Rapoport SI, Reese TS, Westergaard E. Osmotic opening of tight junctions in cerebral endothelium. J. Comp. Neurol. 1973; 152: 317-25.
56. 56. Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood - brain barrier. Ann. N.Y. Acad. Sci. 1980; 481: 250-67.
57. 57. Rapoport SI, Robinson PJ. Tight junctional modification as the basis of osmotic opening of the blood - brain barrier. Am. J. Physiol. 1986; 238: R421-31.
58. 58. Neuwelt EA. (ed.). Implications of the Blood - Brain Barrier and its Manipulation, Vol. 2. Clinical Implications. Plenum Press, New York. 1989.
59. 59. Neuwelt EA, Goldman D, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood - brain barrier disruption: Prolonged survival and preservation of cognitive function. J. Clin. Oncol. 1991; 9: 1580-90.
60. 60. McKhann GM, Goldsborough MA, Borowicz LM et al. Cognitive outcome after coronary artery bypass: A one-year prospective study. Ann. Thorac. Surg. 1997; 63: 510-15.
61. 61. Raymond JJ, Robertson DM, Dinsdale HB. Pharmacological modification of bradykinin induced breakdown of the blood - brain barrier. Can. J. Neurol. Sci. 1986; 13: 214-20.
62. 62. Elliot PJ, Hayward NJ, Dean RL, Blunt DG, Bartus RT. Intravenous RMP-7 selectively increase uptake of carboplatin into rat brain tumors. Cancer Res. 1996; 56: 3998-4005.
63. 63. Bartus RT, Elliot PJ, Hayward NJ, Dean RL, McEwen E, Fisher SK. Bradykinin permeation of the blood - brain barrier: Evidence for a sensitive auto-regulated, receptor mediated system. Immunopharmacology 1996; 33: 270-8.
64. 64. Sanovich E, Bartus RT, Friden PF, Dean RL, Le HQ, Brightman MW. Pathway across blood - brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 1995; 705: 125-35.
65. 2 inhalation in newborn and adult-rats. Exp. Physiol. 1995; 80: 117-28.
66. 66. Rapoport SI. Blood - Brain Barrier in Physiology and Medicine. Raven Press, New York. 1976.
67. 67. Greig NH. Drug delivery to the brain by blood - brain barrier circumvention and drug modification. In: Neuwelt EA (ed.). Implications of the Blood - Brain Barrier and its Modification, Vol. 1. Basic Science Studies. Plenum, New York. 1989; 311-67.
68. 68. Anderson BD. Prodrugs for improved CNS delivery. Adv. Drug Delivery Rev. 1996; 19: 171-202.
69. 69. Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood - brain barrier. J. Neurochem. 1987; 49: 1651-8.
70. 70. Smith QR, Aoyagi M, Rapoport SI. Structural specificity of the brain capillary neutral amino acid transporter. Soc. Neurosci. Abtsr. 1989; 15: 1025.
71. 71. Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa. Clin. Neuropharmacol. 1994; 17: S1-6.
72. 72. Takada Y, Greig NH, Vistica DT, Rapoport SI, Smith QR. Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood - brain barrier. Cancer Chemother. Pharmacol. 1991; 29: 89-94.
73. 73. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide (peptide) nucleic-acid analog through the blood - brain-barrier in vivo. Proc. Natl Acad. Sci. USA 1995; 92: 5592-6.
74. 74. Wu DF, Yang J, Pardridge WM. Drug targeting of a peptide radio-pharmaceutical through the primate blood - brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 1997; 100: 1804-12.
75. 75. Friden PM. Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood - brain barrier. J. Control. Release 1997; 46: 117-28.
76. 76. Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries: Model system of blood - brain barrier transport. J. Biol. Chem. 1987; 262: 15214-19.
77. 77. Huwyler J, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 1996; 93: 14164-9.
78. 78. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptors. Physiol. Rev. 1987; 67: 520-82.
79. 79. Hill JM, Ruff MR, Weber RJ, Pert CB. Transferrin receptors in rat brain: Neuropeptide-like pattern and relationship to iron distribution. Proc. Natl Acad. Sci. USA 1985; 82: 4553-7.
80. 80. Saunders NR, Dziegielewska KM. Barriers in the developing brain. News Physiol. Sci. 1997; 12: 21-31.